Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

BACKGROUND: Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality. METHODS: Here we describe the rationale and design of the P...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, David, Suhr, Ole B., Dyck, Peter J., Litchy, William J., Leahy, Raina G., Chen, Jihong, Gollob, Jared, Coelho, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594468/
https://www.ncbi.nlm.nih.gov/pubmed/28893208
http://dx.doi.org/10.1186/s12883-017-0948-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594468/
https://www.ncbi.nlm.nih.gov/pubmed/28893208
http://dx.doi.org/10.1186/s12883-017-0948-5

Ejemplares similares